Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Clinical management of the hypereosinophilic syndromes.

Authors
Type
Published Article
Journal
Expert Review of Hematology
1747-4094
Publisher
Informa UK (Taylor & Francis)
Publication Date
Volume
5
Issue
3
Identifiers
DOI: 10.1586/ehm.12.14
PMID: 22780208
Source
Medline
License
Unknown

Abstract

Hypereosinophilic syndromes (HESs) are rare disorders characterized by marked hypereosinophilia that is directly responsible for organ damage or dysfunction. Different pathogenic mechanisms have been discovered in patient subgroups leading to the characterization of myeloproliferative and lymphocytic disease variants. In the updated terminology, idiopathic HES is now restricted to patients with HES of undetermined etiology. The practical clinical approach of patients with the different HES variants is reviewed herein, focusing on specific diagnostic tools and therapeutic options. Corticosteroids, hydroxyurea and IFN-α remain the classical agents for treatment of most patients with HESs. The specific role of therapeutic compounds that have become available more recently, namely, tyrosine kinase inhibitors and IL-5 antagonists, is discussed.

Statistics

Seen <100 times